Kneitz S - Search Results

1

miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro.

Krebs M, Solimando AG, Kalogirou C, Marquardt A, Frank T, Sokolakis I, Hatzichristodoulou G, Kneitz S, Bargou R, Kübler H, Schilling B, Spahn M, Kneitz B. Krebs M, et al. Among authors: kneitz s, kneitz b. J Clin Med. 2020 Mar 2;9(3):670. doi: 10.3390/jcm9030670. J Clin Med. 2020. PMID: 32131507 Free PMC article.

2

Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.

Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, Riedmiller H, Kneitz B. Schubert M, et al. Among authors: kneitz s, kneitz b. PLoS One. 2013 Jun 14;8(6):e65064. doi: 10.1371/journal.pone.0065064. Print 2013. PLoS One. 2013. PMID: 23798998 Free PMC article.

3

MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.

Kalogirou C, Spahn M, Krebs M, Joniau S, Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H, Kneitz B. Kalogirou C, et al. Among authors: kneitz s, kneitz b. Int J Mol Sci. 2013 Oct 29;14(11):21414-34. doi: 10.3390/ijms141121414. Int J Mol Sci. 2013. PMID: 24173237 Free PMC article.

4

Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.

Kneitz B, Krebs M, Kalogirou C, Schubert M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Ströbel P, Gessler M, Riedmiller H, Spahn M. Kneitz B, et al. Among authors: kneitz s. Cancer Res. 2014 May 1;74(9):2591-603. doi: 10.1158/0008-5472.CAN-13-1606. Epub 2014 Mar 7. Cancer Res. 2014. PMID: 24607843

5

Impact of miR-21, miR-126 and miR-221 as prognostic factors of clear cell renal cell carcinoma with tumor thrombus of the inferior vena cava.

Vergho DC, Kneitz S, Kalogirou C, Burger M, Krebs M, Rosenwald A, Spahn M, Löser A, Kocot A, Riedmiller H, Kneitz B. Vergho DC, et al. Among authors: kneitz s, kneitz b. PLoS One. 2014 Oct 3;9(10):e109877. doi: 10.1371/journal.pone.0109877. eCollection 2014. PLoS One. 2014. PMID: 25279769 Free PMC article.

6

miR-221 Augments TRAIL-Mediated Apoptosis in Prostate Cancer Cells by Inducing Endogenous TRAIL Expression and Targeting the Functional Repressors SOCS3 and PIK3R1.

Krebs M, Behrmann C, Kalogirou C, Sokolakis I, Kneitz S, Kruithof-de Julio M, Zoni E, Rech A, Schilling B, Kübler H, Spahn M, Kneitz B. Krebs M, et al. Among authors: kneitz s, kneitz b. Biomed Res Int. 2019 Nov 14;2019:6392748. doi: 10.1155/2019/6392748. eCollection 2019. Biomed Res Int. 2019. PMID: 31828111 Free PMC article.

7

Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.

Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B. Spahn M, et al. Among authors: kneitz s, kneitz b. Int J Cancer. 2010 Jul 15;127(2):394-403. doi: 10.1002/ijc.24715. Int J Cancer. 2010. PMID: 19585579

8

The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis.

Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M. Schubert M, et al. Among authors: kneitz s, kneitz b. Adv Urol. 2012;2012:612707. doi: 10.1155/2012/612707. Epub 2012 Jan 31. Adv Urol. 2012. PMID: 22400018 Free PMC article.

9

Combination of expression levels of miR-21 and miR-126 is associated with cancer-specific survival in clear-cell renal cell carcinoma.

Vergho D, Kneitz S, Rosenwald A, Scherer C, Spahn M, Burger M, Riedmiller H, Kneitz B. Vergho D, et al. Among authors: kneitz s, kneitz b. BMC Cancer. 2014 Jan 15;14:25. doi: 10.1186/1471-2407-14-25. BMC Cancer. 2014. PMID: 24428907 Free PMC article.

10

Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality.

Nekova TS, Kneitz S, Einsele H, Bargou R, Stuhler G. Nekova TS, et al. Among authors: kneitz s. Cell Cycle. 2016 Dec;15(23):3203-3209. doi: 10.1080/15384101.2016.1241915. Epub 2016 Nov 10. Cell Cycle. 2016. PMID: 27831832 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters